Heart Failure With Preserved Ejection Fraction (HFpEF) Clinical Trial
Official title:
Differences in Cardiopulmonary Exercise Capacity According to Coronary Microvascular Dysfunction and Body Composition in Patients With Suspected Heart Failure With Preserved Ejection Fraction
The correlation of coronary microvascular function and body composition with cardiopulmonary exercise capacity will be assessed in patients with heart failure with preserved ejection fraction.
We will select the patients with chest pain or ischemic symptoms with non-obstructive coronary artery disease (<50% stenosis) in coronary angiography and preserved ejection fraction (≥50%) in echocardiography. All patients will undergo body composition analysis and adenosine stress echocardiography with the evaluation of coronary artery blood flow by Doppler echocardiography and maximal oxygen consumption (VO2 max) by cardiopulmonary exercise test (CPET). Left ventricular end-diastolic pressure will be assessed during coronary angiography. Coronary flow reserve (CFR) is defined as the ratio of peak to baseline mean diastolic velocity of coronary blood flow. The correlation of CFR and body composition with cardiopulmonary exercise capacity will be assessed. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05371496 -
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
|
Phase 2 | |
| Recruiting |
NCT05441839 -
UK Heart Failure With Preserved Ejection Fraction
|
||
| Completed |
NCT01989299 -
Ventricular Tachyarrhythmia Detection by Implantable Loop Recording in Patients With Heart Failure and Preserved Ejection Fraction
|
||
| Terminated |
NCT03909295 -
An Open-label Extension Study Evaluating Safety and Tolerability of LCZ696 in Subjects Who Completed PARAGON-HF in Japan.
|
Phase 3 | |
| Completed |
NCT04327024 -
Study of Verinurad in Heart Failure With Preserved Ejection Fraction
|
Phase 2 | |
| Active, not recruiting |
NCT05136820 -
Flow Regulation by Opening the SepTum in Patients With Heart Failure; a Prospective, Randomized, Sham-controlled, Double-blind, Global Multicenter Study
|
N/A | |
| Completed |
NCT03988634 -
Changes in NT-proBNP, Safety, and Tolerability in HFpEF Patients With a WHF Event (HFpEF Decompensation) Who Have Been Stabilized and Initiated at the Time of or Within 30 Days Post-decompensation (PARAGLIDE-HF)
|
Phase 3 | |
| Recruiting |
NCT03876223 -
Women's Ischemia Syndrome Evaluation (WISE) Pre-HFpEF
|
||
| Completed |
NCT04232345 -
A Study to Assess the Effect AZD4831 in Japanese and Chinese Healthy Volunteers
|
Phase 1 | |
| Recruiting |
NCT05792059 -
DevElopMent of Clinical PATHwaYs to the Diagnosis of Heart Failure With Preserved Ejection Fraction
|
||
| Completed |
NCT03843060 -
A Phase 1 Study to Assess the Pharmacokinetics of AZD9977 Administered Alone and in Combination With Itraconazole in Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT01714752 -
Evaluation of Left Ventricular Filling Pressures During Exercise
|
N/A | |
| Completed |
NCT06036186 -
Study for the Treatment of Heart Failure With Preserved Ejection Fraction Associated With High Blood Pressure Using Right Atrial Pacing Controlled by the PressurePaceTM System
|
N/A | |
| Recruiting |
NCT05383287 -
Characteristics, Phenotypes, and TRAITS of Heart Failure With Preserved Ejection Fraction (TRAITS-HFpEF)
|
||
| Completed |
NCT03877224 -
DETERMINE-preserved - Dapagliflozin Effect on Exercise Capacity Using a 6-minute Walk Test in Patients With Heart Failure With Preserved Ejection Fraction
|
Phase 3 | |
| Active, not recruiting |
NCT04847557 -
A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT Trial
|
Phase 3 |